Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology Corporation (Nasdaq: PDSB) announced its management will present at the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. The presentation will cover updates on three ongoing Phase 2 clinical trials for PDS0101 and the progression of PDS0102 and PDS0103 into human trials. A pre-recorded presentation will be available on January 10 at 7:00 am ET. Investors can register for the conference HERE.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced on December 20, 2021, that it granted an inducement equity award of 20,000 shares to Michael Lalond, the new Director of Quality Assurance. This grant, valued at an exercise price of $8.87 per share, is part of Mr. Lalond's employment compensation. The shares vest over four years, with the first quarter vesting on December 20, 2022. PDS Biotech focuses on developing immunotherapies using its proprietary Versamune® technology to enhance immune response against various cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the resumption of recruitment for its Phase 2 clinical trial evaluating PDS0101 (Versamune®-HPV16) in advanced HPV cancers, following Institutional Review Board (IRB) approval. The trial, led by the National Cancer Institute (NCI), assesses the combination of PDS0101 with immune-modulating agents for patients who have not responded to standard therapies. The recruitment pause was administrative, and ongoing treatment for enrolled patients was uninterrupted. This trial aims to enhance clinical outcomes for those with limited options.

PDS Biotechnology Corporation (Nasdaq: PDSB) reported a net loss of approximately $7.0 million for Q3 2021, up from $3.9 million in Q3 2020. Research and development expenses increased to $3.7 million, driven by personnel and clinical study costs. The company's cash and cash equivalents stood at $69.7 million as of September 30, 2021. Progress was made in their VERSATILE-002 Phase 2 trial for PDS0101, with enrollment milestones achieved. PDS Biotech also announced a licensing agreement with the National Cancer Institute (NCI) and hired Matthew Hill as the new CFO.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced a licensing agreement with the National Cancer Institute for TARP-related intellectual property to enhance its oncology pipeline. Approximately 470,000 patients are expected to be diagnosed with TARP-associated cancers annually. PDS0102, utilizing the Versamune® technology with TARP, has shown promising preclinical results by inducing tumor-targeted T-cells. The license ensures patent protection until 2034, indicating strong growth potential in treating cancers like acute myeloid leukemia, prostate, and breast cancer.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced a licensing agreement with the University of Georgia for COBRA antigens, which will be integrated into its infectious disease immunotherapy pipeline, specifically PDS0202, a candidate for a universal flu vaccine. This partnership aims to enhance PDSB's Versamune^® T-cell activating technology, addressing the global issue of seasonal influenza. The potential of PDS0202 lies in its ability to generate a robust immune response against multiple influenza strains, which could significantly reduce annual flu cases.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced that Dr. Lauren V. Wood, Chief Medical Officer, will present at the 2021 International Head and Neck Cancer Conference from November 2-4, 2021. The seminar titled "New Drugs in the Fight Against Head & Neck Cancer" will focus on innovative treatment methods for head and neck cancer, featuring PDSB's proprietary Versamune^® technology and its potential impact on HPV-associated cancers. The conference aims to enhance collaboration among health professionals, patients, and drug companies in cancer research and treatment.

PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy firm, announced on October 19, 2021, the granting of nonstatutory stock options to key personnel including CFO Matthew Hill and others. The options allow the purchase of shares at an exercise price of $12.03, based on the stock's closing price on the grant date. Each option vests over four years, promoting long-term employment. The company focuses on developing cancer immunotherapies utilizing its Versamune^® technology, aiming to enhance T-cell responses against various cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced a temporary suspension of recruitment in the Phase 2 clinical trial (NCT04287868) for PDS0101, evaluating its potential in advanced HPV cancers. This decision is not due to safety or efficacy concerns but rather administrative issues. The National Cancer Institute expects the recruitment to resume shortly without affecting the clinical data timeline. Interim data suggests PDS0101 may significantly improve outcomes for patients with limited options.